recombinant spike protein subunit vaccine  (SK Bioscience Co Ltd)

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: a The experimental design is shown; Mouse pups were inoculated at weaning with 5 µg SARS-CoV-2 recombinant protein (RP) vaccine b , c adjuvanted with PBS (RP-PBS), AddavaxTM (RP-Ad), or LNP (RP-LNP) or SARS-CoV-2 mRNA-LNP vaccine d , e at 1 µg, 5 µg, or 10 µg. b – e Sera were collected from mouse pups at indicated time points after weaning/vaccination and SARS-CoV-2 full length Spike (S) protein-specific IgG concentrations b , d and IgM concentrations c , e were measured by ELISA. Each point represents the geometric mean with error bars indicating 95% confidence interval (CI) of the geometric mean. Mouse groups were n = 5 (RP vaccinated groups) or n = 6 (mRNA vaccinated groups). Sample IgG and IgM concentrations were plotted to a standard curve of known concentrations of a S-specific IgG monoclonal antibody and are reported as arbitrary units (AU)/mL. Data are shown as geometric mean concentrations with 95% confidence intervals. All panels show results of one experiment that is representative of two independent biological replicates. Group geometric mean IgG concentrations were compared at 4 weeks and 8 weeks post-vaccination to corresponding within-group 1 week concentrations by repeated measures (RM) one-way ANOVA with Tukey’s post hoc test (* indicates p < 0.05, ** indicates p < 0.01). Schematic for a created with Biorender.

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: a The experimental design is shown; Female mice were mated with males and then were inoculated at day 5 after introduction of males with SARS-CoV-2 mRNA-LNP vaccine at 0.1 µg, 1 µg, or 5 µg. b , c . b Sera were collected from mouse pups at indicated time points after weaning/vaccination and SARS-CoV-2 full length Spike (S) protein-specific IgG concentrations were measured by ELISA. One phase-decay was fitted to IgG data (R 2 > 0.90 for all groups) with each point representing a single mouse pup and each line representing the decay curve for one dose group (0.1 µg n = 2; 1 µg n = 12; 5 µg n = 7). c Dams were vaccinated with 5 µg mRNA-LNP and serum was collected from dams ( n = 6) and pups ( n = 48) at day of weaning. Each point represents the geometric mean with error bars indicating 95% confidence interval (CI) of the geometric mean. Sample IgG concentrations were plotted to a standard curve of known concentrations of a S-specific IgG monoclonal antibody and are reported as arbitrary units (AU)/mL. Data are shown as geometric mean concentrations with 95% confidence intervals (* indicates p < 0.05 by unpaired two-tailed Student’s T test). Schematic for Figure a created with Biorender.

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: a The experimental design is shown; Female mice were mated with males and then were inoculated at day 5 after introduction of males with SARS-CoV-2 mRNA-LNP vaccine (5 µg) or PBS and pups were vaccinated at weaning with PBS, SARS-CoV-2 recombinant protein (RP) with Addavax (RP-Ad) or empty lipid nanoparticle (RP-LNP), or SARS-CoV-2 mRNA vaccine (mRNA-LNP). b – e Sera were collected from mouse pups at indicated time points after weaning/vaccination and SARS-CoV-2 full length Spike (S) protein-specific IgG concentrations were measured by ELISA. For each vaccine condition ( b , PBS; c , mRNA-LNP; d , RP-Ad; e RP-LNP; n = 4-6 mice per group) at each time point, geometric mean IgG concentrations were compared between the matAb+ and matAb- groups by one-way ANOVA with post hoc Šidák test. Each point represents the geometric mean with 95% confidence intervals. f , g Column graphs depict SARS-CoV-2 IgG concentrations for matAb- f and matAb+ g mice at 18 weeks post-vaccination for each vaccine condition, with each point representing a single mouse and central bars representing geometric mean concentration and 95% CI. Group geometric mean IgG concentrations were compared by one-way ANOVA with Tukey’s post hoc test with significance level of group comparison indicated by nested brackets. For all panels, sample IgG concentrations were plotted to a standard curve of known concentrations of a SARS-CoV-2 IgG monoclonal antibody and are reported as arbitrary units (AU)/mL with samples for which IgG was below the threshold of detection (TOD, represented by horizontal dotted lines) imputed to half the TOD (represented by the x axis). Central points/bars and error bars for all panels represent geometric mean concentrations with 95% confidence intervals. Significance levels for statistical hypothesis testing are indicated (* indicates p < 0.05, ** indicates p < 0.01, ns indicates p ≥ 0.05). All panels show results of one experiment that is representative of two independent biological replicates. Schematic for a created with Biorender.

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Concentration Assay, Comparison

Journal: NPJ Vaccines

Article Title: Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model

doi: 10.1038/s41541-024-00901-4

Figure Lengend Snippet: Female mice were mated with males and then were inoculated at day 5 after introduction of males with SARS-CoV-2 mRNA-LNP vaccine (5 µg) or PBS and pups were vaccinated at weaning with PBS, SARS-CoV-2 recombinant protein (RP) with Addavax (RP-Ad) or empty lipid nanoparticle (RP-LNP), or SARS-CoV-2 mRNA vaccine (mRNA-LNP). Sera were collected from mouse pups at 4 weeks after weaning/vaccination and neutralization efficacy measured by focus reduction neutralization test (FRNT) of pseudotyped vesicular stomatitis virus (VSV) expressing SARS-CoV-2 D614G spike glycoprotein. Column graphs depict FRNT50 for matAb- a and matAb+ b mice for each vaccine condition, with each point representing a single mouse and central bars representing geometric mean concentration and 95% CI. c Presents all groups on a single column graph for ease of depiction of within-vaccine condition comparisons of matAb- and matAb- mice. Group geometric mean IgG concentrations were compared by one-way ANOVA with Tukey’s post hoc test with significance level of group comparison indicated by nested brackets. Samples for which no neutralization was detected at the lowest dilution were imputed to half the TOD (dotted line). Significance levels for statistical hypothesis testing are indicated (* indicates p < 0.05, ** indicates p < 0.01, ns indicates p ≥ 0.05).

Article Snippet: Recombinant spike protein subunit vaccines were prepared by diluting 5 μg recombinant spike protein in 50 μL diluent; diluent for Addavax TM -adjuvanted vaccines consisting of 25 μL PBS and 25 μL Addavax TM (Invivogen, San Diego, CA) and diluent for lipid nanoparticle-adjuvanted vaccines consisted of a concentration of LNP corresponding to the mRNA-LNP vaccine brought to a total volume of 50 μL with PBS.

Techniques: Recombinant, Neutralization, Virus, Expressing, Concentration Assay, Comparison

Journal: Applied Microbiology and Biotechnology

Article Title: Current view on novel vaccine technologies to combat human infectious diseases

doi: 10.1007/s00253-021-11713-0

Figure Lengend Snippet: Ongoing clinical trials for novel vaccine compounds against infectious diseases in humans in phases 1–3 listed by the FDA by the November 1, 2021 ( https://www.clinicaltrials.gov/ )

Article Snippet: COVID-19 , NCT04760743 , 2020-12-17 , Recombinant Spike protein subunit vaccine , I (P) , SK bioscience Co., Ltd.

Techniques: Clinical Proteomics, Control, Recombinant, Produced, Synthesized, Plasmid Preparation, Liposomes, Vaccines